3Ma X,Does M,Raza A,et al.A Myelodysplastic syndromes:incidence and survival in the United States.Cancer,2007,109(8):1536-1542.
4Zagonel V. 5 -aza-2-decitabine induces trilineage response in unfavourable myelodysplastic syndromes [ J ]. Leukemia, 1993,7 (11) :30-35.
5Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes results of a phase Ⅲ randomized study [J]. Cancer, 2006,106 ( 8 ) : 1794-1803.
6Wij ermans PW, Lubbert M, Verhoff G, et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5 aza-2-decitabine in 177 patients [ J ]. Ann Hemato1,2005,84 ( Suppl 13 ) :9-17.
7Wijermans P,Lubbert M, Verhoff G, et al. Lowdose 5-Aza-2 deoxycytidine, a DNA hpyomethylating agent, for the treatment of highrisk myelodysplastic syndrome:A multicenter phase Ⅱ study in elderly patients[J]. J Clin Oncol,2000,18(5) :956-962.
8Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high- risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy : final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol, 2011:29 ( 15 ) _. 1987 - 1996.
9张之南,沈悌.血液学诊断及疗效标准.第3版,北京,科学出版社,2006.279-281.
10Saba HI. Decitabine in the treatment of myelodysplastic syn- dromes. Ther Clin Risk Manag, 2007 ;3 (5) : 807 -817.
